

## DAFTAR PUSTAKA

1. Sood R, Mukhopadhyaya S. Approach to a patient with haemoptysis and normal chest x-ray. *Clinical Medicine, JIACM* 2002;3(1):14-22.
2. Abal AT, Nair P, Cherian J. Haemoptysis: aetiology, evaluation and outcome a prospective study in a third world country. *Respir Med* 2001;95:548-52.
3. Jean BE. Clinical assessment and management of massive hemoptysis. *Crit Care Med* 2000;28:1642-7.
4. Bone R. Massive hemoptysis: diagnosis and treatment. In: RP Dellinger RT, JL Zimmerman, editor. *Critical care a concise review*. 1<sup>st</sup> ed. Illinois: American College of Chest Physicians; 1995. p. 257-61.
5. Sudariato, Sinar, Mahyudin, *Jurnal Berita Kesehatan : Jurnal Kesehatan*, Vol. XII No. 1 (Juni, 2020)
6. Jacob L, Robert W. Hemoptysis : diagnosis and management. *America Family Physician* 2005;72:1253-60.
7. Deng, Guo, Jiong, Reisz G. Clinical efficacy of carbazochrome sodium sulfonate combined with phentolamine in treatment for hemoptysis tuberculosis 2011
8. Mufrodi, Heru Wiwien. Uji perbandingan klinis antara carbazochrome dengan vitamin K + vitamin C. Jakarta: Universitas Indonesia; 2014.
9. Busroh I, editor. Surgical management of massive hemoptysis. Presented on the 14<sup>th</sup> Asia Pacific on diseases of chest and The 7<sup>th</sup> congress of the Indonesian association of pulmonogist; 1996 June; Denpasar.
10. Winurti MC. Hasil Terapi konservatif pada penderita batuk darah di RSUPPersahabatan. Jakarta: FKUI; 2000.
11. Swidarmoko B. Batuk darah (hemoptisis). In: Swidarmoko B, Susanto AD, editors. *Pulmonologi intervensi dan gawat darurat napas*. Jakarta:FKUI; 2010. p. 28-53.
12. Flores RJ, Sandur S. Massive hemoptisis. *Hospital Physician* 2006 May;25:212-8.
13. Fishman A. *Fishman's pulmonary disease and disorder*. 3<sup>rd</sup> ed. New York: McGraw-Hill 1998. p. 379-82.

14. Cahill BC, Ingbar DH. Massive hemoptysis. Assessment and management. *Clin Chest Med* 1994;15:144-68.
15. Depari RESS. Kriteria pulang pasien batuk darah dan evaluasi dalam satu bulan di rumah sakit persahabatan. Jakarta: Universitas Indonesia; 2010.
16. Weitz JI. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Bonow R, Mann D, Zipes D, Libby P, editors. *Braunwald's heart disease a textbook of cardiovascular medicine*. 9<sup>th</sup> ed. Philadelphia: Elsevier Saunders; 2012. p. 1844-66.
17. Rhee JW, Sabatine MS, Lillyed LS. Acute coronary syndrome. In: Lilly L, editor. *Pathophysiology of heart disease*. 5<sup>th</sup> ed. Baltimore: Lippincott Williams & Wilkins; 2011. p. 161-89.
18. Physiology of hemostasis system (primary, secondary, fibrinolysis).
19. Mackman N. Triggers, targets and treatments of thrombosis. *Nature* 2008.
20. Marieb, Elaine N, Hoehn, Katja. In: Cummings B, editor. *Human Anatomy & Physiology*. 8<sup>th</sup> ed. San Francisco: Benjamin Cummings; 2010.
21. Watson SP. Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. *Curr Pharm Biotechnol* 2009.
22. Hemostasis and thrombosis. In: Kumar, Abbas, Fausto, Mitchell, editors. *Robbins basic pathology*. 8<sup>th</sup> ed. Philadelphia: Saunders Elsevier; 2007.
23. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. *J Thromb Haemost* 2009.
24. Skandalakis JE. Respiratory system In: Skandalakis JE, editor. *Skandalakis' surgical anatomy The embryology and anatomic basis of modern surgery*; 2004.
25. Prakash UB, Freitag L. Hemoptysis and bronchoscopy induced hemorrhage. In: UB P, editor. *Bronchoscopy*. New York: Raven Press; 1994.
26. Ball JA. Pulmonary manifestations of Goodpasture's syndrome. *Atiglomerular basement membrane disease and related disorders*. *Clin Chest Med* 1998.
27. Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. *Chest* 2000;118:126- 31.
28. Lecainche L. Long term outcome of idiopathic pulmonary hemosiderosis in

- children. *Medicine* 2000;79:318-26.
29. Orenstein DM. Cystic fibrosis: a 2002 update. *J Pediatr* 2002;140:156-64.
  30. Hiyama. Cryptogenic hemoptysis and smoking. *Chest* 2002;121:1375-6.
  31. Gawat napas hemoptisis. Standar pelayanan medis SMF Paru. Jakarta: Departemen Kesehatan RI Ditjen Pelayanan medik RSUP Persahabatan; 2007. p. 51-2.
  32. Rosmiati H, Gan VHS. Antikoagulan, antitrombosit, trombolitik dan hemostatik. In: Ganiswarna SG, Setiabudy R, Suyatna FD, Purwastyastuti, Nafrialdi, editors. *Farmakologi dan terapi*. 4<sup>th</sup> ed. Jakarta: FKUI; 1995.
  33. Dewoto HR, P. SWB. Vitamin dan mineral. In: Ganiswarna SG, Setiabudy R, Suyatna FD, Purwastyastuti, Nafrialdi, editors. *Farmakologi dan terapi*. 5<sup>th</sup> ed. Jakarta: Bagian farmakologi fakultas kedokteran UI; 2011. p. 714- 37.
  34. Lee RE. Ascorbic acid and the peripheral vascular system *Annals of the New York Academy of Sciences* 1961;92:295- 301. hh. Sendo T, Itoh Y, Aki K, Oka M, Oishi R. Carbazochrome sodium sulfonat (AC-17) reverses endothelial barrier dysfunction through inhibition of phosphatidylinositol hydrolysis in cultured porcine endothelial cells. *Naunyn- Schmeideberg's Arch Pharmacol* 2003;368:175-80. Funahara Y, Sumarmo, A AS, Harun SR, R S-D, Nathin MA, et al. Protection against marked plasma leakage in dengue haemorrhagic fever by infusion of carbazochrome sodium sulfonate (AC-17). *Southeast Asian J Trop Med Public Health* 1987;18(3):356-61.
  35. Tassniyom S, Vasanawathana S, Dhiensiri T, Nisalak A, Chirawatkul A. Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: a randomized, controlled trial. *The Journal of Pediatrics* 1997;130(4):525-8.
  36. Solomonov A, Fruchter O, Zuckerman T, Brenner B, Yigla M. Pulmonary hemorrhage: A novel mode of therapy. *Respiratory Medicine* 2009;103:1196-200.
  37. Tscheikuna J, B BC, Naruman C, Maranetra N. Tranexamic acid in patients with hemoptysis. *J Med Assoc Thai* 2002;85(4):399-404.
  38. Graff GR. Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid. *Respiration* 2001;68:91

39. Mondoni M, Carlucci P, Job S, Parazzini EM, Cipolla G, Pagani M, Tursi F, Negri L, Fois A, Canu S, Arcadu A, Pirina P, Bonifazi M, Gasparini S, Marani S, Comel AC, Ravenna F, Dore S, Alfano F, Sferrazza Papa GF, Di Marco F, Centanni S, Sotgiu G. Observational, multicentre study on the epidemiology of haemoptysis. *Eur Respir J*. 2018 Jan 4;51(1):1701813. doi: 10.1183/13993003.01813-2017. PMID: 29301924.
40. Bahtiar, Cottenet J, Beltramo G, et al. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. *Eur Respir J* 2015; 46: 503–511.
41. Rezky, Ramadhaniah F, Syarif S. Studi Tinjauan Pustaka: Risiko Kejadian Kanker Paru pada Penderita Tuberkulosis Paru. *J Epidemiol Kesehat Indones*. 2021;4(1):29-36. doi:10.7454/epidkes.v4i1.3410
42. Intan, Irfa, Sahoo S, Panigrahi MK, Naik S, Mohapatra PR. Rasmussen's aneurysm masquerading as mass lesion. *BMJ Case Rep*. 2020 Feb 16;13(2):e232669. doi: 10.1136/bcr-2019-232669. PMID: 32066578; PMCID: PMC7046436.
43. Shebani A, Hnish M, Elmelliti H, Lutf Abdussalam A. Massive Hemoptysis in Pulmonary Tuberculosis From Rasmussen Pseudoaneurysm. *Cureus*. 2022 Oct 10;14(10):e30117. doi: 10.7759/cureus.30117. PMID: 36381825; PMCID: PMC9644153.
44. Yang, Song & Mai, Zhuanying & Zheng, Xiangzhen & Qiu, Yueling. 2015. Etiology and an Integrated Management of Severe Hemoptysis Due to Pulmonary Tuberculosis. *Journal of Tuberculosis Research*. 03. 11-18. 10.4236/jtr.2015.31002.
45. Gupta S, Dutta P, Anand S, Kanchan R. Correlation of Bleeding Time and Clotting Time with ABO Blood Grouping Among 1-year Medical Students. *Natl J Physiol Pharm Pharmacol* [Internet]. 2021;11(6):1. Available from: <https://www.ejmanager.com/fulltextpdf.php?mno=34016>
46. Lundgren FL, Costa AM, Figueiredo LC, Borba PC. (2010). Hemoptysis in a referral hospital for pulmonology. *Jornal Brasileiro de Pneumologia*,36: 320-4.
47. Masdi Mufrodi. Perbandingan Efektivitas Carbazochrome Sodium Sulfonat (AC

- 17) ditambah Vitamin K dan vitamin C dengan vitamin K ditambah vitamin C Dalam Menghentikan batuk Darah Karena Penyakit Paru = comparative effectiveness carbazochrome sodium sulfonate (AC 17) plus Vitamin K and Vitamin C with vitamin K plus vitamin C in stop hemoptysis due to pulmonary disease [Internet]. Fakultas Kedokteran Universitas Indonesia; 1970 [cited 2024 Sept 4]. Available from: <https://lib.ui.ac.id/detail?id=20389777&lokasi=lokal>
48. Luo Y, Zhao X, Releken Y, Yang Z, Pei F, Kang P. Hemostatic and Anti-Inflammatory Effects of Carbazochrome Sodium Sulfonate in Patients Undergoing Total Knee Arthroplasty: A Randomized Controlled Trial. *J Arthroplasty*. 2020 Jan;35(1):61-68. doi: 10.1016/j.arth.2019.07.045. Epub 2019 Aug 6. PMID: 31471180.
49. Wang J, Fu H, Wang B, Yu J gang, Liu X, Liu Y, et al. Carbazochrome attenuates acute lung injury in septic rats by inhibition of parkin-mediated mitochondrial autophagy. *Journal of Radiation Research and Applied Sciences*. 2022 Sept;15(3):12–20. doi:10.1016/j.jrras.2022.05.017
50. Karlafti E, Tsavdaris D, Kotzakioulafi E, Kougias L, Tagarakis G, Kaiafa G, Netta S, Savopoulos C, Michalopoulos A, Paramythiotis D. Which Is the Best Way to Treat Massive Hemoptysis? A Systematic Review and Meta-Analysis of Observational Studies. *J Pers Med*. 2023 Nov 26;13(12):1649. doi: 10.3390/jpm13121649. PMID: 38138876; PMCID: PMC10744930.
51. Prey B., Francis A., Williams J., Krishnadasan B. Evaluation and Treatment of Massive Hemoptysis. *Surg. Clin. N. Am.* 2022;102:465–481. doi: 10.1016/j.suc.2021.11.002.